Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, 400016, China.
Division of Biostatistics and Data Science, Department of Population Health Science, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Eur J Surg Oncol. 2019 Aug;45(8):1364-1372. doi: 10.1016/j.ejso.2019.02.013. Epub 2019 Feb 19.
Role of surgery in the management of de novo stage IV breast cancer (BC) remains controversial. We aimed to determine the survival benefit of primary surgery on the basis of metastatic pattern.
A retrospective cohort study based on the SEER database was conducted to identify patients with de novo stage IV BC diagnosed between 2010 and 2015. Patients were divided into surgery and non-surgery group, and propensity score weighting was used to balance clinicopathologic factors between groups.
Of 8142 de novo stage IV BC patients, 1891 (23%) cases were managed with surgery and 6251 (77%) cases were managed without surgery. There were 3821 all-cause deaths and 3291 BC specific deaths over a median follow-up of 22 months. The weighted 3-year overall survival (OS) for the surgery group was 54.5%, compared to 47.7% (P < 0.001) for the non-surgery group. The magnitude of the survival difference with surgery was significantly correlated with metastatic patterns (P<0.05). Significant survival improvements in surgery group compared with non-surgery group were observed in patients with bone-only metastasis (adjusted HR = 0.83, P < 0.05) or multiple metastases with bone involved (adjusted HR = 0.76, P < 0.05), whereas survival inferiority of surgery was found for patients with multiple visceral organs-only metastases (adjusted HR = 2.08, P < 0.05).
The survival benefit offered by surgery for de novo stage IV BC varies by metastatic patterns. Decisions for primary surgery of de novo stage IV BC patients should be tailored according to metastatic pattern.
手术在新发 IV 期乳腺癌(BC)治疗中的作用仍存在争议。我们旨在根据转移模式确定手术的生存获益。
本研究基于 SEER 数据库进行了一项回顾性队列研究,以确定 2010 年至 2015 年间诊断为新发 IV 期 BC 的患者。将患者分为手术组和非手术组,并使用倾向评分加权来平衡组间临床病理因素。
在 8142 例新发 IV 期 BC 患者中,有 1891 例(23%)接受了手术治疗,6251 例(77%)未接受手术治疗。中位随访 22 个月后,有 3821 例患者发生全因死亡,3291 例患者发生 BC 特异性死亡。手术组的加权 3 年总生存率(OS)为 54.5%,而非手术组为 47.7%(P<0.001)。手术治疗的生存差异与转移模式显著相关(P<0.05)。与非手术组相比,仅骨转移(调整后的 HR=0.83,P<0.05)或伴有骨受累的多发转移(调整后的 HR=0.76,P<0.05)患者的手术组生存改善明显,而仅多发内脏器官转移的患者手术组的生存劣于非手术组(调整后的 HR=2.08,P<0.05)。
手术对新发 IV 期 BC 的生存获益因转移模式而异。新发 IV 期 BC 患者的手术治疗决策应根据转移模式进行调整。